Posted by Michael Wonder on 22 Jul 2025
ProMIS Neurosciences granted fast track designation by US FDA for PMN310 in the treatment of Alzheimer’s disease
21 July 2025 - ProMIS Neurosciences today announced that the US FDA has granted fast track designation to PMN310, the Company’s lead therapeutic candidate in development for the treatment of Alzheimer’s disease.
The ongoing PRECISE-AD Phase 1b trial is evaluating PMN310 in patients with early Alzheimer's disease.
